Astute Medical Raises $13M for Protein Biomarker Dx Development
March 11, 2011
Astute Medical Raises $13M for Protein Biomarker Dx Development
The company said it will use the money, which is an extension of a $26.5 million Series B round completed in May 2010, to advance and expand research, development, and validation of protein biomarker-based laboratory tests.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Astute Medical Completes $40M Series C Funding Round
June 8, 2012 / ProteoMonitor - Yale-Led Group Links Protein Markers to Kidney Injury in Cardiac Surgery Patients
August 26, 2011 / ProteoMonitor - Proteomics Firms Net More than $8.75M in IRS Funds; Bulk of Awards Aimed at Diagnostics Work
November 5, 2010 / ProteoMonitor - Multi-Site Validation Study Published Supporting Astute Medical's NephroCheck AKI Test
February 8, 2013 / ProteoMonitor - Astute Medical Launches European Sales of Nephrocheck AKI Risk Assessment Test
October 19, 2012 / ProteoMonitor